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BACKGROUND: There are relatively few articles addressing long-term follow-up in women with breast cancer at very young ages.
METHODS: We have updated and extended our population-based analysis of breast cancer diagnosed at the age p30 years in North-
west England to include an extra 15 patients with mutation testing in BRCA1, BRCA2 and TP53, with 115 of 288 consecutive cases
being tested. Kaplan–Meier curves were generated to assess overall survival, contralateral breast cancer and other second primaries.
RESULTS: Survival analysis of all 288 patients showed poor overall survival, although this improved from a 15-year survival of only 46%
in those diagnosed between 1980 and 1989 to 58% in those diagnosed between 1990 and 1997 (P¼0.05). Contralateral breast
cancer rates were at a steady rate of 0.6 per 1000, although the rates in mutation carriers were B2 per 1000. Altogether, 16 BRCA1,
9 BRCA2 and 6 TP53 mutations have now been found among the 115 cases on whom DNA analysis has been performed. BRCAPRO
accurately predicted the number of carriers for BRCA1 and BRCA2 and was sensitive and specific at the 10 and 20% threshold,
respectively. However, BRCAPRO did not seem to give any weight to DCIS, which accounted for two BRCA1 carriers and three
TP53 carriers and overpredicted mutations at the high end of the spectrum, with only 6 of 11 (54%) with a 490% probability having
identifiable BRCA1/2 mutations.
INTERPRETATION: Rates of new primaries are predicted to some extent by mutation status. BRCAPRO is useful at determining those
patients aged p30 years to be tested.
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Mutations in BRCA1, BRCA2 and TP53 account for a proportion of
early-onset and familial breast cancer. These mutations confer a
lifetime breast cancer risk of 43–85% (Varley et al, 1997; Ford
et al, 1998). Several studies have investigated the frequency of
BRCA1/2 and TP53 mutations in families with breast and/or
ovarian cancer or Li–Fraumeni (LFS) or LFS-like (LFL) syndrome
(Sidransky et al, 1992; Varley et al, 1997; Gayther et al, 1998; Peto
et al, 1999; Loman et al, 2001). Among breast cancer cases
unselected for family history (FH), the prevalence of BRCA1/2
mutations is dependent on the population studied and on the age
at diagnosis of malignancy (Fitzgerald et al, 1996; Krainer et al,
1997; Peto et al, 1999; Loman et al, 2001). Although these papers
have addressed the incidence of BRCA1/2 in young women with
breast cancer, data are still sparse in women diagnosed at very
young ages (p30 years) and data are lacking for TP53.
Lalloo et al (2003, 2006) reported on the frequency and
penetrance of BRCA1/2 and TP53 mutations in early-onset breast
cancer in earlier papers. These papers showed a predominance of
BRCA1/2 mutations in familial aggregations of breast cancer, with
penetrance estimates of breast cancer as high as 80–90% by 70
years of age. This paper presents a detailed analysis of survival,
contralateral breast cancer and other tumour incidence in index
cases aged p30 years, both with and without BRCA1/2 or TP53
mutations. It also presents results of including an extended series
of BRCA1/2 and TP53 index cases diagnosed with breast cancer at
p30 years of age.
METHODS
Patients
The 288 original patients were ascertained from a population-
based series of consecutive breast cancers from the North Western
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sCancer Intelligence Service (NWCIS) diagnosed with breast cancer
at or under 30 years of age between 1 January 1980 and
31 December 1997. Diagnoses were confirmed using hospital
records and pathology reports. Those patients who were proven to
have a histological diagnosis other than breast carcinoma were
excluded. Patients were approached through their consultant for
permission to be interviewed and, after informed consent, to
provide blood for DNA testing. A detailed three-generation
pedigree was obtained along with copies of hospital notes, where
available. Family histories of malignancy were confirmed through
the cancer registry, hospital notes or death certificates.
Patients were classified as familial, LFS, LFL or non-familial
groups on the basis of FH at initial diagnosis. Familial patients
were defined as those with a FH of breast cancer o65 years of age
or ovarian cancer at any age in first- or second-degree relatives at
the time of the index cases’ primary breast cancer diagnosis. Both
LFS and LFL were defined as in Table 1.
A further series of 84 patients diagnosed with breast cancer at or
under 30 years of age who had tested positive for mutations in
BRCA1/2 or TP53 were included for some analyses of contralateral
and other tumour risks to enrich the inherited subtypes. Of these
patients, 24 were diagnosed in the northwest after 31 December 1997.
Kaplan–Meier (KM) survival curves from diagnosis of breast
cancer were derived from the original series alone, with ductal
carcinoma in situ (DCIS) included and excluded. A comparison
between cases diagnosed before and after 1990 was also under-
taken. Kaplan–Meier curves were derived for the occurrence
of contralateral breast cancer after the initial diagnosis and for
other cancer diagnoses following initial breast cancer diagnosis
with the inclusion of mutation carriers from the additional data
set. Kaplan–Meier curves for contralateral breast cancer from
diagnosis were derived using the enriched data set with a
confirmed FH or mutation: comparisons were made between no
FH (sporadic): BRCA1; BRCA2; TP53; and FH but no mutation.
Mutation analysis
All samples were screened for mutations in BRCA1, BRCA2 and
TP53 as described previously (Lalloo et al, 2003). Since then, further
mutation screening of BRCA1 and BRCA2 has been undertaken
using direct sequencing and multiple ligation-dependent probe
amplification, which is a dosage test to detect large single or multiple
exon deletions or duplications. An additional 15 samples have
become available for mutation testing from the original p30 series.
Pathology
Pathology was taken from the original pathology report and
NWCIS entry. All available tumours from patients who had
donated blood samples for DNA analysis were reviewed by a single
pathologist (FK). Oestrogen receptor (ER) (6F11 Novocastra,
Bannockburn, IL, USA), PR (PGR312 Novocastra) and HER2
(c-erbB2 CB11 Novocastra) immunohistochemistry was performed
in cases in which tissue was available. Both ER and PR were scored
using the Allred (Quick) score based on the assessment of both
proportion and intensity of staining. Her-2 was scored according
to standard protocol (Ellis et al, 2004). The ER status was
considered negative if the Quick score was 0/8 or if o5% cells were
positive by immunohistochemistry. Her-2 was regarded as positive
if the tumour showed gene amplification by fluorescent in situ
hybridisation (FISH) or, in the absence of FISH, if the
immunohistochemical score was 3þ (scale of 0–3).
Model prediction
Carrier probabilities of BRCA1 and BRCA2 using BRCAPRO and
Myriad were calculated using the CancerGene software package
(CaGene version 4.3.2) from the University of Texas Southwestern
Medical Center (Houston, TX, USA). Additional information about
CancerGene is available at http://www.utsouthwestern.edu. The
Manchester scoring system was used for comparison (Evans et al,
2004). Carrier status was calculated at last follow-up or death of the
affected woman to take into account bilateral disease and newer
FH. Assessments were made for a 10 and 20% detection rate for
each gene and BRCA1/2 combined.
Statistical analysis
Assessment of KM curves was undertaken by w
2 test by comparing
each grouping separately with all others for BRCA1, BRCA2, TP53,
familial mutation negative and sporadic mutation negative.
Ninety-five percent confidence intervals (CIs) were derived for
survival and contralateral tumour incidence.
RESULTS
A total of 276 women were registered on the NWCIS with
confirmed early-onset primary breast carcinoma diagnosed
between 1 January 1980 and 31 December 1997 in the strict
regional boundaries. At original ascertainment between 1993 and
December 1997, 116 (42%) women were dead and 160 (58%) were
alive. As of December 2008, 144 (52%) women were dead and
132 (48%) were alive. The age of diagnosis and grade of tumour
did not significantly differ between the living and dead cases.
The mean age at diagnosis was 28 years and 3 months (range
18 years 5 months to 30 years 11 months). Consultant permission
to approach the patient was refused for 26 living patients
(4 subsequently came forward unprompted). Of the remaining
135 cases, 102 consented to participate, 32 refused and 1 could not
be traced. Blood samples were available from a further five deceased
patients, and were tested after family consent. Further blood
samples were obtained from an additional 8 of 12 women affected at
the appropriate age and study period on the NWCIS, but outside
the strict regional boundaries. As such, genetic status could be
established for 115 women from the NWCIS who developed breast
cancer at p30 years of age (15 more than our previous report).
In all, 46 patients (42%) had a significant FH, which was
consistent with LFS or LFL in 6 cases. A further five women had a
FH of breast cancer, which was not consistent with the original
study (breast cancer in third-degree relatives or 465 years of age).
The remaining 64 cases had no known FH of breast or ovarian
cancer at the time of diagnosis and were classified as non-familial.
Molecular analysis
Overall, pathogenic mutations in BRCA1, BRCA2 and TP53 were
identified in 31 women: 26 of 53 (49%) familial and 5 of 62 (8%)
Table 1 Diagnostic criteria for Li–Fraumeni syndrome and
Li–Fraumeni-like syndrome
Li–Fraumeni syndrome
(Li et al, 1988)
Li–Fraumeni-like syndrome
(Birch et al, 1994)
Proband o45 years with a sarcoma Proband o45 years with childhood
tumour, sarcoma, brain tumour or
adrenocortical tumour
Plus first-degree relative o45 years
with any cancer
Plus first- or second-degree relative
in the same lineage with typical LFS
tumour at any age
Plus additional first- or second-degree
relative in the same lineage aged
o45 years with any cancer or
a sarcoma at any age
Plus another first- or second-degree
relative in the same lineage with any
cancer o60 years
Abbreviation: LFS¼Li–Fraumeni syndrome.
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snon-familial cases (Tables 2–4). Three patients with BRCA1/2
mutations were sporadic at the time of diagnosis and one patient
had only a paternal grandmother with breast cancer aged 65 years.
In all four cases, the history changed over follow-up. Two women
developed bilateral disease (cases 9 and 16, Table 5) and in the
other two, a FH of ovarian cancer and breast cancer developed
after their own diagnosis.
Pathogenic BRCA1 mutations were identified in 16 women
(14%) diagnosed with breast cancer at p30 years of age. BRCA2
mutations were detected in nine women (8%). Pathogenic TP53
mutations were found in 5 patients (5%) including 3 of 6 (50%)
of the LFS/LFL subgroup. The updated analysis demonstrated
an additional TP53 mutation: 659A4G in a family fulfilling
LFS criteria, four further BRCA1 mutations (2682C4T, del exons
1–17, del exons 5–17, 1953DupG) in four familial breast cancers
and 1 BRCA2 mutation (1058C4A) out of the 15 additional
samples obtained since our last report (Lalloo et al, 2006). The
pathology characteristics based on mutation status are presented
in Table 3. Table 4 shows a more detailed breakdown of grade 3
tumours. Only in grade 3 triple-negative breast cancer does the
rate of BRCA1 mutation among sporadic cases increase above
10% (2 of 16). However, the overall detection rate in all triple-
negative grade 3 cases including those with a FH was 10 out of
27 (37%).
An additional 30 patients with BRCA1 mutations diagnosed at p30
years of age after 31 December 1979 and 19 with BRCA2 mutations
with the same criteria were identified from our clinic mutation
database. In addition, six TP53 carriers diagnosed at p30 years of age
were found. In all, 13 of the total 84 mutation carriers (46 BRCA1,2 7
BRCA2,1 1TP53) have had risk-reducing contralateral mastectomy
(RRM) representing 20% of the total. We are not aware of any RRMs
being performed in the remaining patients.
Survival
Of the 288 cases in the population-based series, 18 had carcinoma
in situ as their initial diagnosis. Of these cases, two had comedo
DCIS and were shown to have a TP53 mutation. They subse-
quently died from a primary glioma and retroperitoneal sarcoma,
respectively. Two patients died from subsequent ipsilateral
invasive breast cancer and one from non-cancer-related
event. Survival analysis from diagnosis in the whole data set
is presented in Figure 1. Survival decreases below 50% at the
15-year point. However, this masks a difference between those
cases diagnosed before and after 1990. Rates of 5-, 10- and
15-year survival were 69% (95% CI: 65–73%), 58% (95% CI:
54–62%) and 57% (95% CI: 53–61%), respectively, in 133 women
diagnosed after 1990 compared with 61% (95% CI: 57–65%),
49% (95% CI: 45–53%) and 46% (95% CI: 42–50%), respec-
tively, in 155 women diagnosed before 1990 (hazard ratio 1.38
P¼0.05).
Contralateral breast cancer incidence
Contralateral breast cancer incidence is shown in Figure 2A and B.
The incidence of contralateral breast cancer up to 20 years of
follow-up is 0.6% per year. (Figure 2A). In all, 19 contralateral
breast cancers occurred in follow-up (Table 5): 1 in a TP53 carrier,
Table 2 Histology and vital status on 276 incident breast cancer patients
p30 years and 12 additional cases from the NWCIS
Total Alive (%)
Deaths from breast
or other cancer
IDC grade 3 ER negative 40 30 (75%) 10
IDC grade 3 ER positive 19 15 (79%) 4
IDC grade 3 no receptor
status
60 25 (42%) 35
All grade 3 119 70 (59%) 49
IDC grade 2 37 14 (38%) 23
IDC grade 1 9 4 (45%) 5
DCIS 18 13 (72%) 5
IDC no grade on pathology
report
90 35 (39%) 53
Lobular invasive 8 4 (50%) 4
Scirrhous 3 1 (33%) 2
LCIS 2 2 (100%) 0
Spheroidal 2 0 (0%) 2
Mucinous 1 0 (0%) 1
SCC nipple 1 1 (100%) 0
Total 288 144 144
Abbreviations: DCIS¼ductal carcinoma in situ;E R ¼oestrogen receptor; IDC¼
invasive Ductal Carcinoma; LCIS¼Lobular Carcinoma in situ; NWCIS¼North
Western Cancer Intelligence Service; SCC¼Squamous Cell Carcinoma.
Table 3 Pathology characteristics of 115 patients with DNA testing
Total BRCA1 BRCA2 TP53 Any mutation
IDC grade 3 ER negative 35 10 0 0 10/35
IDC grade 3 ER positive 16 1 4 0 5/16
IDC grade 3 no receptor
status
16 2 2 0 4/16
IDC grade 2 15 0 2 0 2/15
IDC grade 1 4 0 0 0 0/4
DCIS 11 2 0 3 5/11
IDC no grade 10 0 0 1 1/10
Lobular invasive 4 1 0 0 1/4
LCIS 2 0 0 0 0/2
Spheroidal 2 0 1 1 2/2
Mucinous 1 0 0 0 0/1
SCC nipple 1 0 0 0 0/1
Total 115 16 (14%) 9 (8%) 5 (5%) 29/115 (25%)
Abbreviations: DCIS¼ductal carcinoma in situ;E R ¼oestrogen receptor; IDC¼
invasive Ductal Carcinoma; LCIS¼Lobular Carcinoma in situ;S C C¼Squamous Cell
Carcinoma.
Table 4 Frequency of constitutional BRCA1 and BRCA2 mutation in grade 3 IDC with oestrogen receptor status and triple negative status in a population
based study of breast cancer patients p30 years
All IDC grade
3 ER negative
All IDC grade
3 triple negative
Grade 3 IDC no hormone
receptor status available
Grade 3
ER positive
All
Grade 3
All breast
cancer cases
BRCA1: all cases 10/35 (29%) 10/27 (37%) 2/16 (14%) 1/16 (6%) 13/67 (19.5%) 16/115 (14%)
Sporadic 2/22 (9%) 2/16 (12.5%) 0/7 0/11 2/40 (5%) 2/62 (3%)
Familial 8/13 (61%) 8/11 (73%) 2/9 (22%) 1/5 (20%) 11/27 (41%) 14/53 (26%)
BRCA2: all cases 0/35 0/27 2/16 (12%) 4/16 (25%) 6/67 (9%) 9/115 (8%)
Sporadic 0/22 0/16 1/7 (14%) 0/11 1/40 (2.5%) 1/62 (1.5%)
Familial 0/13 0/11 1/9 (11%) 4/5 (80%) 5/27 (18%) 8/53 (15%)
Abbreviations: ER¼oestrogen receptor; FISH¼fluorescent in situ hybridisation. In all, 37 of 67 (55%) grade 3 tumours had HER2 status assessed on pathology review. Eight
(22%) were HER2 positive on FISH analysis.
Outcome of early-onset breast cancer
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carrier data set, there is a 2% annual risk of contralateral breast
cancer up until 15 years, after which the number of patients is too
small for any stable estimate (Figure 2B).
Other cancer incidence
The incidence of non-breast primary cancer was 4.2% at 25 years
(Supplementary Table). Surprisingly, no ovarian cancer has so far
occurred even among BRCA1/2 carriers, given the fact that the age
of these women now without oophorectomy is 38–55 years.
Indeed, in 620.5 years of follow-up in the enhanced data set of
72 women with BRCA1/2 mutations (censored at date of
oophorectomy in 13 women), no ovarian cancers have occurred.
Of 59 women with intact ovaries, 25 are now 440 years of age.
Model performances
Performance of the BRCAPRO model and myriad tables can be
seen in Tables 5 and 6. BRCAPRO performed well, especially in
unilateral cases, although it seemed to overestimate in bilateral
cases (P¼0.05). In isolated sporadic unilateral cases, the only
patient exceeding the 10% threshold (25.8%) with BRCAPRO was a
Jewish woman who did not have a mutation. In 11 families with a
predicted BRCA1/2 mutation status 490% (10.47 predicted), only
6 BRCA1/2 mutations were found (1 in BRCA2). Two of the TP53
carriers had a predicted BRCA1/2 score of 490% (95.3, 94.3%).
The prediction of DCIS cases is also presented in Table 5. Although
both the BRCA1 carriers with DCIS reached the 10% combined
threshold, it is clear that this was because of the very strong FH.
Indeed, there seems to be no weighting for DCIS, as sporadic cases
had a 0% rating for BRCA1 and even those with a FH were no more
likely in BRCAPRO to be a BRCA1 carrier than an unaffected
sibling.
The myriad model did not perform well with poor sensitivity,
especially at the 20% level. The Manchester score was partly
developed using initial data from this series before the extended
follow-up and addition of 15 women. Using the updated
pathology-adjusted Manchester score (Evans et al, 2009), sensi-
tivity at the 20% level improved from 80 to 88% (Table 6).
Table 5 Performance of BRCAPRO and Myriad models in predicting BRCA1/2 mutation status
Number
BRCAPRO
BRCA1
BRCAPRO
BRCA2
BRCAPRO
combined Myriad
BRCA1
actual
BRCA2
actual
Combined
BRCA1+BRCA2
Sporadic breast cancer 64 3.47 2.14 7.6 4.2 2 1 3
Sporadic breast cancer unilateral 54 1.1 1 2.1 3.6 1 1 2
Bilateral breast cancer 17 7.6 3.0 10.6 2.2 4 1 5
Bilateral sporadic 8 2.35 1.15 3.5 0.5 1 0 1
Bilateral family history positive 9 5.3 1.8 7.1 1.7 3 1 4
Familial unilateral 43 10.4 4.4 14.8 6.4 11 7 18
DCIS 11 0.60 0.35 0.95 0.4 2 0 2
Total 115 19.2 8.4 27.6 12.4 16 92 5
Abbreviation: DCIS¼ductal carcinoma in situ.
5 years
Breast cancer
CIS excluded
62% (95% CI
59–65%)
51% (95% CI
48–54%)
46% (95% CI
43–49%)
44% (95% CI
40–48%)
DCIS
DCIS excluded
DCIS included
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Figure 1 Survival from breast cancer diagnosis in 288 breast cancer cases aged p30 years and diagnosed between 1980 and 1997.
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sDISCUSSION
This study has updated the previous comprehensive analysis of FH
and mutation analysis for all three high-risk breast cancer genes in
women diagnosed with breast cancer aged p30 years to include
an additional 15 patients with 5 new pathogenic mutations.
The analysis of contralateral disease, non-breast primaries and
survival has been enriched with additional patients diagnosed at
Population-based_series
BC1 aged 30 years
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Figure 2 (A) Contralateral breast cancer cumulative incidence in all incident breast cancer cases aged p30 years. (B) Contralateral breast cancer
cumulative incidence in BRCA1, BRCA2 and TP53 breast cancer cases at p30 years of age and in mutation-negative groups.
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sthe age of p30 years from our mutation database. We have
previously published the prevalence of both BRCA1/2 and TP53
mutations in this cohort (Lalloo et al, 2003), demonstrating a
higher prevalence of TP53 mutations than previously expected.
The mutation detection rate in familial breast cancer in these
three genes is B50% (26 of 53), demonstrating the importance
of accurately documenting a FH when estimating the likelihood
of a mutation carrier. Few mutations were found in those
women without a FH. These data would therefore not support
the testing of BRCA1/2 in patients below the age of 31 years
without a FH of breast cancer. In particular, even in sporadic cases
with grade 3 cancers, the detection rate was only 5%. Among
grade 3 triple-negative sporadic cases, the rate of mutation
detection was only 12.5% (2 of 16). Lakhani et al (2005) reported
data on the likelihood of breast cancer being caused by a BRCA1
mutation by pathological grade and ER status at various ages in
women not selected by FH. These data were also from an
unselected series. Women aged between 20 and 29 years with
grade 3 ER-negative breast cancers had a 35% chance of a BRCA1
mutation, with a similarly high risk for women aged 30–34 years
at 26.5%. Only after the age of 34 years did the risks fall below
10% (Lakhani et al, 2005). However, these figures include all
women, even those with a FH. Unfortunately, it seems that some
clinicians have misinterpreted these data and called for all women
o35 years of age with pathological grade 3 and ER-negative
breast cancer to be tested, or has offered testing on the basis of a
10–20% testing threshold. Our population-based data confirm a
similar 29% risk for young women (age o31 years). This suggests
that only triple-negative, pathological grade 3 breast cancers in
women o31 years of age qualify for testing, irrespective of FH,
on the basis of guidelines using a 10% threshold in outbred
populations. Clearly, the CIs are wide on these numbers, and
further studies to assess the rates of mutations in sporadic
triple-negative patients will help inform models and scoring
systems further. For instance, a recent North American study
demonstrated mutations in 9% of triple-negative breast cancer
patients aged o40 years without, or with minimal, FH of breast
or ovarian cancer (Young et al, 2009). However, this study
did not describe the FH. Nevertheless, use of pathology in our
pathology-adjusted Manchester score (Evans et al, 2009) improved
sensitivity at the 20% threshold by detecting two further mutations
at the cost of testing only three further samples.
The data in the current analysis demonstrate the improvement
in survival in breast cancer, which is seen in many countries. In the
United Kingdom, a more formal approach for breast surgery
including axillary node dissection and treatment of all ipsilateral
breast tissue (radiotherapy in those undergoing local excision)
was highlighted in 1990 (Fentiman and Mansel, 1991). This more
formalised treatment schedule may in part explain the signi-
ficant improvement in survival from diagnosis with time. Never-
theless, overall survival is still poor in this group of young women.
This is likely to be related to a more aggressive phenotype with less
hormonally sensitive cancers (Figueiredo et al, 2007; Anders et al,
2008). The poor prognosis seems to particularly apply to breast
cancer patients at age o35 years and is consistent between studies
in the United Kingdom, North America and Asia (Nixon et al,
1994; Jmor et al, 2002; Han and Kang, 2010).
The diagnosis of a second primary tumour should prompt
the clinician to consider a TP53 mutation. One patient with a renal
carcinoma and a de novo TP53 mutation went on to develop
a sarcoma behind the remaining kidney that was subjected to
regular screening radiation from intravenous urograms. An
oesophageal cancer also occurred in a BRCA2 carrier. However,
surprisingly, no ovarian cancers occurred in BRCA1/2 carriers,
even though 21 women have lived beyond 40 years of age without
an oophorectomy. Population studies have indicated that the
subsequent ovarian cancer risk is higher if an individual is
diagnosed with breast cancer at a young age, particularly if
there is a FH of ovarian cancer (Bergfeldt et al, 2002). This is
most likely to suggest a high probability of a BRCA1/2 mutation
rather than another mechanism increasing ovarian cancer risk.
The data from our study do not suggest a higher ovarian
cancer risk in women with known mutations with early-onset
breast cancer, compared with mutation carriers with later-onset
disease.
This study assessed the performance of mutation prediction
models in this population-based data set. We chose to assess the
models at last follow-up to determine how the models dealt with
new contralateral disease. Direct comparisons with the Manchester
scoring system are inappropriate, as this system was partly
developed from the original data set at the time of diagnosis.
Another model, BOADICEA, also used this data set in development
(Antoniou et al, 2008). BRCAPRO (Parmigiani et al, 1998)
performs well, especially in unilateral cases. As no non-Jewish
sporadic case (even the adopted individuals) reached the 10%
combined threshold even at the time of diagnosis, this supports the
hypothesis that, in Western populations, the rates of BRCA1/2
mutations even in early-onset breast cancer cases without a FH are
low. An adopted sporadic case would need to be diagnosed at the
age of p24 years to breach the threshold using BRCAPRO.
Nevertheless, BRCAPRO does seem to overestimate the BRCA1/2
probabilities in bilateral cases. It is also interesting to note the
handling of DCIS. Although both BRCA1 carriers with DCIS were
identified using the 10% combined threshold, they were as likely to
be a carrier as an unaffected sibling. It seems that no weight is
given to DCIS to increase either the BRCA1 or BRCA2 probability
of either the individual or the family in BRCAPRO. Ductal
carcinoma in situ at the age of p30 years is clearly an important
diagnosis, as 45% of the 11 cases had a pathogenic mutation, with
DCIS being a particular marker for a TP53 mutation. The myriad
tables (Frank et al, 2002) do not have a specific readout for
bilateral disease and therefore should probably not be used to
Table 6 Sensitivity and specificity of BRCAPRO and Myriad tables at the 10 and 20% level for BRCA1, BRCA2 and both genes combined
Model/scoring system Sensitivity Specificity Positive predictive value Negative predictive value
BRCAPRO combined 10% 23/25 (92%) 65/90 (72%) 23/48 (48%) 65/67 (97%)
BRCAPRO combined 20% 20/25 (80%) 73/90 (81%) 20/37 (54%) 73/78 (94%)
BRCAPRO BRCA1 10% 14/16 (87.5%) 72/99 (72%) 14/41 (34%) 72/74 (97%)
BRCAPRO BRCA2 10% 4/9 (44%) 78/106 (74%) 4/32 (12.5%) 78/83 (94%)
Myriad 10% 18/25 (72%) 76/90 (84%) 18/32 (56%) 76/83 (92%)
Myriad 20% 8/25 (32%) 86/90 (96%) 8/12 (75%) 86/103 (83%)
MANCHESTER combined 10% 25/25 (100%) 57/90 (63%) 25/58 (43%) 57/57 (100%)
MANCHESTER combined 20% 20/25 (80%) 77/90 (86%) 20/33 (60%) 77/82 (94%)
MANCHESTER BRCA1 10% 15/16 (94%) 73/99 (73%) 15/41 (37%) 73/74 (99%)
MANCHESTER BRCA2 10% 6/9 (67%) 78/106 (74%) 6/34 (18%) 78/81 (96%)
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sassess families with this disease. No patient using the Myriad tables
had a score above 39.2% for likelihood of a mutation. There also
seems to be a degree of overestimation at the top end of the
BRCAPRO model. The model does not allow for sensitivity of
mutation techniques, as scores of up to 100% are possible. The
model also does not allow for the possibility of other high-
penetrance genes, as two of the TP53 carriers had scores above
94%, yet their FHs were consistent with LFS. We have estimated
that a combined score of 40þ using the Manchester score suggests
a very high probability of a BRCA1/2 mutation (Evans et al,
2009). Using this threshold, six of seven samples had a detectable
mutation.
The strengths of this study are that it is population based and
has obtained DNA samples on the great majority of living cases.
Overall death rates and second primary rates are secure because of
the cancer intelligence service.
This study does have some limitations. The pathology reports on
patients diagnosed before 1990 had little information with regard
to grade and do not have information regarding hormone receptor
status. It was not possible to determine reliable survival data on the
basis of tumour grade as a result of this deficiency. However, in the
group that submitted a blood sample, a detailed pathological
review was possible in most cases.
Summary
This analysis has shown an improvement in survival for women with
very early-onset breast cancer in more recent years. There are high
rates of BRCA1, BRCA2 and TP53 mutations in women aged p30
years with a FH. Among sporadic patients, mutations are generally
in those with grade 3 triple-negative tumours. Rates of further
primary tumours other than contralateral breast cancer are not high,
except in TP53 carriers, and very young-onset BRCA1/2 carriers do
not seem to be at enhanced risk of ovarian cancer compared with
other BRCA1/2 carriers. Contralateral breast cancer rates seem stable
at B0.6% annually in all women and at 2–3% in mutation carriers.
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